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Abstract
Background Cigarette smoking is a modifiable risk factor that influences the disease course of patients with multiple scle-
rosis (MS). However, in patients with a clinically isolated syndrome (CIS), there are conflicting results about the association 
between smoking and the risk of a subsequent MS diagnosis. The aim of this study was to determine the risk of clinically 
definite MS (CDMS) in smoking and non-smoking patients at time of a first demyelinating event.
Methods Two hundred and fifty patients, aged 18–50 years, were included in our prospective CIS cohort. At time of the first 
neurological symptoms, patients completed a questionnaire about smoking habits. Cox regression analyses were performed 
to calculate univariate and multivariate hazard ratios for CDMS diagnosis in smoking and non-smoking CIS patients.
Results One hundred and fourteen (46%) CIS patients were diagnosed with CDMS during a mean follow-up of 58 months. 
In total, 79 (32%) patients smoked at time of CIS. Sixty-seven % of the smoking CIS patients were diagnosed with CDMS 
during follow-up compared to 36% of the non-smoking CIS patients (p < 0.001). Smoking at time of CIS was an independent 
predictor for CDMS diagnosis (HR 2.3; p = 0.002). Non-smoking CIS patients who had a history of smoking did not have 
a higher risk for CDMS than those who had never smoked.
Conclusions Smoking at time of CIS was an independent risk factor for a future CDMS diagnosis. This is an additional 
argument to quit smoking at time of the first attack of suspected MS.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory autoim-
mune disease, influenced by environmental factors in geneti-
cally susceptible individuals [1]. This results in demyelina-
tion, axonal loss, and neurodegeneration [1–3]. The course 
of MS is heterogeneous in severity and prognosis [1].
One of the environmental factors influencing the course 
of MS is cigarette smoking [4]. Studies in MS patients and 
healthy controls consistently provide evidence that both 
active and passive smoking result in an increased risk of 
MS and disease progression [4–7]. Smoking does not only 
increase MS risk, it also shortens the time to the secondary 
progressive phase of MS (SPMS) [8, 9]. It has been shown 
that after cessation of smoking, negative effects slowly 
decrease, independent of the cumulative dose of smoking 
[8, 10].
Studies show that the risk of MS associated with HLA 
genotypes is influenced by smoking. This interaction leads 
to a much stronger effect on MS risk than the cumulative 
effect of genetic risk factors and smoking together [11, 12].
In the majority of cases (85–90%), MS starts as a clini-
cally isolated syndrome (CIS), followed by novel episodes 
of neurological symptoms resulting from inflammation of 
the central nervous system (CNS). However, a CIS attack 
can also remain a single event [13].
Only a few studies are available in CIS patients that inves-
tigated the effect of smoking on subsequent MS risk. Firm 
conclusions in these studies are hampered by several meth-
odologic issues such as low patient numbers, retrospective 
designs [14–16], or considerable numbers of CIS patients 
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treated with interferon beta [17, 18]. On the other hand, sev-
eral studies in MS patients do suggest a link between smok-
ing and MS progression [7]. Therefore, we determined the 
effect of smoking on clinically definite MS (CDMS) risk in 
a large prospective cohort of predominantly untreated CIS 
patients. It is important to know if smoking is associated 
with a future MS diagnosis, as smoking is up to now, one 
of the few modifiable risk factors for disease progression 
in MS.
Methods
Patients
Data were collected prospectively from patients with CIS 
at the Neurology Department of Erasmus MC University 
Hospital in Rotterdam, a tertiary referral centre for patients 
with MS. Data collection was in collaboration with several 
regional hospitals in The Netherlands. Included patients 
had their first symptoms between May 2006 and June 2017. 
Patients were aged between 18 and 50 years, with no his-
tory of previous neurological symptoms suggestive of CNS 
demyelination. CIS patients were included within 6 months 
following the first neurological symptoms. Patients with 
alternative diagnoses were excluded from the analyses. At 
baseline, a magnetic resonance imaging (MRI) scan and 
routine laboratory tests were utilized to rule out alterna-
tive diagnoses [19]. Following inclusion, patients were 
reassessed at least annually at the Neurological Outpatient 
Department.
Questionnaire
At baseline, CIS patients completed a questionnaire to gather 
information about smoking habits, including when they first 
started smoking, non- or reduced-smoking periods and how 
many cigarettes were smoked within these periods. Using 
results of the questionnaire, we were able to calculate the 
pack-years per patient.
Standard protocol approvals, and patient consent
This study was approved by the Medical Ethics Committee 
of Erasmus MC Rotterdam. Written informed consent was 
obtained from all patients.
Definitions
A relapse was defined as new symptoms or subacute wors-
ening of existing symptoms after 30 days of improvement, 
or stable disease and no evidence of alternative diagno-
sis. Symptoms had to exist longer than 24 h and not to be 
preceded by fever [20]. All exacerbations were confirmed 
by neurological examination. CDMS was defined as clini-
cal dissemination in space and time with two exacerbations 
and (para) clinical evidence of two separate lesions, as 
described by Poser et al. [21]. Patients who were diagnosed 
with CDMS during follow-up are referred to as CIS–CDMS 
and patients who remained CIS are referred to as CIS–CIS. 
Expanded Disability Status Scale (EDSS) scores were per-
formed annually when patients were diagnosed with CDMS 
[22]. EDSS performed within 3 months after a relapse were 
not used in the analyses. Follow-up was calculated by sub-
tracting CIS date from the last visit date. Patients were 
defined as smokers when they were smoking regularly at 
time of CIS. Non-smokers were those who did not smoke at 
time of CIS. Patients were defined as ex-smokers when they 
were not smoking at time of CIS, but did have a history of 
smoking in the years prior to CIS. To calculate pack-years, 
the number of years smoked was multiplied by the number 
of cigarettes smoked per day/20 in that period.
Statistical analysis
Statistical analyses were done using SPSS, version 21.0 
(SPSS Inc) for Windows and GraphPad Prism5 (GraphPad) 
for Windows. Nominal data comparison between groups was 
done using Chi-square or Fisher’s exact test [gender, type of 
clinical onset, oligoclonal bands (OCB), ≥ 9 T2 lesions on 
baseline MRI, disease modifying therapy (DMT) at time of 
CIS, smoking at time of CIS, SPMS, and alcohol use]. The 
Kolmogorov–Smirnov test was performed to assess normal-
ity of data distribution. To compare continuous data, we 
applied a two-tailed t test (age at onset and follow-up time) 
or when the data were non-parametric, a Mann–Whitney U 
test (time from CIS to CDMS and pack-years). Time to sec-
ond attack was calculated from onset of the first symptoms. 
Cox-proportional hazard regression analyses were used to 
calculate univariate and multivariate hazard ratios (HR). 
Patients who did not have a second attack during follow-
up were considered as censored observations. Hazard ratios 
were also obtained for time to EDSS 4.0 and time to EDSS 
6.0. p values less than 0.05 were considered significant.
Results
Patient characteristics
We included 250 patients who completed the baseline ques-
tionnaire about smoking at time of CIS. Out of these 250 
CIS patients, 114 (46%) patients had a second relapse and 
were diagnosed with CDMS during a mean follow-up time 
of 58.1 months (SD 35.9).
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The median time (interquartile range; IQR) from CIS to 
CDMS was 23.3 months (8.9–44.3). The median time (IQR) 
between the first neurological symptoms and inclusion in the 
study was 1.2 months (0.3–2.9 months).
Fifty-seven (23%) patients who were not yet diagnosed 
with CDMS were treated with DMT. The patient character-
istics are shown in Table 1.
Smokers vs non‑smokers
In total, 79 out of 250 (32%) patients smoked at time of 
CIS. Fifty-three out of 79 (67%) smoking CIS patients were 
diagnosed with CDMS during follow-up compared to 61 out 
of 171 (36%) in the non-smoking CIS patients (p < 0.001). 
The number of pack-years was higher in the group that was 
diagnosed with CDMS (CIS–CDMS) during follow-up than 
in the group that remained CIS (CIS–CIS) (median (IQR) 
CIS–CDMS vs CIS–CIS: 2.4 (0.0–11.9) vs 0.0 (0.0–2.7) 
p = 0.004) (Fig. 1).
There were no differences between smokers and non-
smokers in gender, localisation of first symptoms, age, OCB 
in CSF or MRI characteristics at baseline. Table 2 shows 
patient characteristics for smokers and non-smokers.
Association of smoking at time of CIS with a shorter 
time to CDMS
Patients who smoked at time of CIS had a shorter time to 
CDMS diagnosis than patients who were not active smokers 
(univariate hazard ratio; HR 2.1 p < 0.001) (Fig. 2). Cor-
rections were applied for multiple variables that are associ-
ated with a second attack (OCB in CSF, more than nine T2 
lesions, gadolinium enhancing lesions on baseline MRI, and 
optic neuritis as first symptom, no DMT before CDMS). 
After these adjustments, multivariate COX regression analy-
sis showed smoking as an independent predictor for a second 
attack. The HR was 2.3 (p = 0.002).
In a sub-analysis, we excluded the 50 CIS patients who 
had less than 2 years of follow-up. After exclusion, the 
results remained the same, HR 2.0 (p < 0.001).
Fifty-seven (23%) of the patients received DMT before 
CDMS diagnosis. When we excluded these patients, the HR 
was unchanged 2.0 (p = 0.001).
Smoking in the past
In the group of patients that did not smoke at time of CIS 
(n = 171), 63 (37%) patients had a history of smoking in 
Table 1  Patient characteristics (CIS–CDMS vs CIS–CIS patients)
CIS clinically isolated syndrome, CIS–CDMS patients who are diagnosed with CDMS during follow-up after CIS defined by Poser criteria, CIS–
CIS not diagnosed with CDMS, na not applicable, OCB oligoclonal bands
a P value calculated between CIS–CDMS and CIS–CIS
CIS patients (n = 250) CIS–CDMS (n = 114) CIS–CIS (n = 136) p  valuea
Female sex, no. (%) 189 (75.6) 92 (80.7) 97 (71.3) 0.09
Age, mean (SD), years 33.6 (8.3) 32.6 (7.9) 34.5 (8.5) 0.07
Follow-up time, mean (SD), months 58.1 (35.9) 72.3 (30.4) 46.3 (36.0) < 0.01
Type of clinical onset, no. (%)
 Optic nerve 88 (35.2) 33 (28.9) 55 (40.4) 0.06
 Spinal cord 90 (36.0) 45 (39.5) 45 (33.1) 0.30
 Other localization 72 (28.8) 36 (31.6) 36 (26.5) 0.37
OCB, (> 1 band), (%) 113 (73.9) 63 (81.8) 50 (65.8) 0.02
≥ 9 lesions on T2-weighted images, no. (%) 96 (38.6) 53 (46.9) 43 (31.6) 0.01
DMT at time of CIS, no. (%) 57 (22.8) 26 (22.8) 31 (22.8) 1.00
Smoking at time of CIS, no. (%) 79 (31.6) 53 (46.5) 26 (19.1) < 0.01
Pack-years at time of CIS, median (IQR) 1.0 (0.0–5.9) 2.4 (0.0–9.5) 0.0 (0.0–2.7) < 0.01
Fig. 1  Pack-years in CIS patients. Comparison of pack-years between 
CIS–CIS and CIS–CDMS patients. Horizontal lines and error bars 
indicate median and IQR
 Journal of Neurology
1 3
the past (ex-smokers). Smoking in the past did not pre-
dict CDMS diagnosis in the group of non-smoking CIS 
patients (HR 0.64, p = 0.12). Furthermore, in this non-
smoking group (n = 171), the number of pack-years was 
not correlated with time to CDMS [HR per pack-years: 0.96 
(p = 0.31)].
Smoking at time of CIS and disability later 
in the disease
In this cohort, we collected EDSS data from 96/114 (84%) 
patients who were diagnosed with CDMS. Nineteen patients 
reached an EDSS of 4.0 and eight patients an EDSS of 6.0 
during follow-up. Six out of these eight patients who reached 
an EDSS score of 6.0 or more were smoking at time of 
CIS. The HRs for both EDSS scores were not significant 
[HR for EDSS 4.0: 1.9 (p = 0.18) and HR for EDSS 6.0: 
4.1 (p = 0.09)]. However, there was a trend towards faster 
disability progression in CDMS patients who were smoking 
at time of CIS.
Discussion
In this prospective study of patients included after a first 
attack of suspected MS, we determined the risk of CDMS in 
a cohort of 250, mostly untreated smoking and non-smoking 
CIS patients. We demonstrated that smoking at time of CIS 
is associated with a shorter time to a second clinical attack 
and, therefore, an earlier diagnosis of CDMS.
Smoking is a well-established risk factor for MS and dis-
ease progression after MS diagnosis [4, 5]. This association 
is also found in other auto-inflammatory diseases such as 
rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE) [23, 24].
Studies investigating the influence of smoking on MS 
risk in first attack patients have remained inconclusive, as 
described recently in a systematic review [25]. Three studies 
were relatively small and used retrospective data [14–16]. 
Other studies were large, but patients were treated with 
interferon beta immediately after CIS or 2 years after CIS, 
[17, 18]. Interferon beta treatment could have postponed MS 
diagnosis [26]. Therefore, the potential correlation between 
smoking and MS risk may be overshadowed by this disease-
postponing therapy.
Compared to these studies, the present study has less 
confounding factors, it has a prospective design and only a 
small proportion of patients was treated with DMT before 
CDMS diagnosis.
In the multivariate analysis, we corrected our results for 
currently known predictors for CDMS diagnosis (large num-
ber of T2 lesions, contrast enhancing lesions on baseline 
Table 2  Patient characteristics 
(smoking vs non-smoking CIS 
patients)
CIS clinically isolated syndrome, OCB oligoclonal bands
Smoking CIS 
patients (n = 79)
Non-smoking CIS 
patients (n = 171)
p value
Female sex, no. (%) 58 (73.4) 131 (76.6) 0.59
Age, mean (SD), years 33.9 (7.7) 33.5 (8.5) 0.67
Follow-up time, mean (SD), months 60.7 (30.7) 57.0 (38.1) 0.45
Type of clinical onset, no. (%)
 Optic nerve 25 (31.6) 63 (36.8) 0.42
 Spinal cord 29 (36.7) 61 (35.7) 0.87
 Other localization 25 (31.6) 47 (26.3) 0.50
OCB, (> 1 band), (%) 43 (75.4) 70 (72.9) 0.73
≥ 9 lesions on T2-weighted images, no. (%) 33 (42.3) 63 (36.8) 0.41
DMT at time of CIS, no. (%) 24 (30.4) 33 (19.3) 0.05
CDMS, no. (%) 53 (67.1) 61 (35.7) < 0.01
SPMS, no. (%) 3 (3.8) 5 (2.9) 0.72
Alcohol use, no. of patients (%) 55 (69.6) 79 (46.2) < 0.01
Fig. 2  Time from CIS to CDMS in smoking and non-smoking 
patients. Kaplan–Meier curve for time from CIS to CDMS for 
smoking and non-smoking patients at time of CIS [log-rank test 
p < 0.001)]
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MRI, unique OCB in CSF and localization of CIS) and for 
DMT before CDMS diagnosis [27]. After these corrections, 
smoking remained clearly predictive for CDMS diagnosis. 
Therefore, smoking status can potentially improve prediction 
of a future CDMS diagnosis in CIS patients. Accurately pre-
dicting CDMS diagnosis is important to prevent unnecessary 
treatment of patients with low disease activity [28].
The fact that smoking in the past in current non-smoking 
CIS patients was not associated with CDMS suggests that 
the harmful effects of smoking are reversible. This supports 
results of earlier studies, showing that after cessation of 
smoking, the negative effect on disability progression slowly 
decreases, independent to the cumulative dose of smoking 
[8, 10].
Our study has some limitations. Although the mean fol-
low-up time was long (almost 5 years), there was a wide 
range. To overcome this, we used a COX regression model 
to correct for follow-up time. We also performed a sub-anal-
ysis, where CIS patients with less than 2 years of follow-up 
were excluded. Excluding these patients left 200 patients for 
analysis and did not change our results. Yet, for demonstra-
tion of an association between smoking at time of CIS and 
later disability (EDSS) a longer follow-up would be needed.
Second, there is a possibility that our results are explained 
by potential confounding lifestyle factors such as body mass 
index (BMI) or alcohol use. It has been shown that obesity 
is a risk factor for MS [29]. However, it is not likely that a 
high BMI explained the effect seen here, as obesity is more 
common in non-smokers [30]. A Swedish study showed an 
inverse association of alcohol consumption with MS [31]. 
We did not observe an effect of alcohol use on CDMS diag-
nosis in the regression analysis (data not shown).
Third, a follow-up MRI scan was not performed accord-
ing to a fixed protocol. Instead, we used the classic Poser 
criteria that are based on clinical manifestations to define 
CDMS. Thus, we can only claim an association with clinical 
disease activity but not with lesion accrual on MRI scan.
It is not likely that CIS patients with a second attack dur-
ing follow-up had over-reported smoking at time of CIS. 
Even in case recall would play a serious role here, recall 
of smoking would be expectedly more strong for the ques-
tion of past smoking [32]. Yet, it was only recent smoking, 
more plausibly related to concurrent biological processes 
just before, during and after the first demyelinating attack, 
that showed an association.
The exact influence of ongoing smoking on the progres-
sion of the auto-inflammatory process around a first clinical 
attack of demyelination remains to be determined. It may 
involve several pathways, including both direct and indirect 
influences of tobacco toxins and smoke particles on T cells 
and antigen presenting cells [33].
To conclude, we show in a large prospective cohort of 
CIS patients that smoking at time of CIS is an independent 
risk factor for a future CDMS diagnosis. Smoking status 
could even be a relevant parameter in predictive models on 
a possible MS disease course after CIS. Since smoking is 
a modifiable risk factor, our study draws attention to the 
relevance of counselling patients about smoking. Though 
intervention studies will be difficult to execute, this study 
may provide evidence for the argument to quit smoking for 
patients with a first attack of suspected MS.
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